View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 18, 2017

M&As this week: Thermo Fisher Scientific, Norgine

US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash.

US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash.

The purchase consideration for the acquisition will amount to $7.2bn, including the assumption of $2bn of net debt owed by the target company.

The target company is a Netherlands-based contract development and manufacturing organisation.

"Norgine has reached an agreement for the acquisition of Merus Labs International in a cash deal."

Norgine has reached an agreement for the acquisition of Merus Labs International in a cash deal.

The entire issued and outstanding common shares of the target company will be acquired at a price of $1.65 a share, which represents an enterprise value of approximately $342m for Merus Labs.

The acquisition will be financed through existing cash and recently secured credit facilities.

Netherlands-based Norgine specialises in gastroenterology, hepatology, cancer and supportive care, while Canadian firm Merus Labs is a specialist pharmaceutical company focused on oncology, women's health, cardiovascular, urology, infectious diseases.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena